Brown JR et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388(4):319-32. Abstract
Byrd JC et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized phase III trial. J Clin Oncol 2021;39(31):3441-52. Abstract
Dreyling M et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: Results from the randomized triangle trial by the European MCL network. ASH 2022;Abstract 1.
Hillmen P et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. EHA 2021;Abstract S145.
Kater AP et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities NEJM Evidence 2022;1(7). Abstract
O’Brien SM et al. Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol 2021;11:720704. Abstract
Robak T et al The role of Bruton’s kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers (Basel) 2022;14(3):771. Abstract
Sharma S et al. New acalabrutinib formulation enables co-administration with proton pump inhibitors and dosing in patients unable to swallow capsules (ELEVATE-PLUS). ASH 2021;Abstract 4365.
Shirley M. Bruton tyrosine kinase inhibitors in B-cell malignancies: Their use and differential features. Target Oncol 2022;17(1):69-84. Abstract
Tam CS et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): A randomised, controlled, phase 3 trial. Lancet Oncol 2022;23(8):1031-43. Abstract
Wang H et al. Bruton tyrosine kinase inhibitors in B-cell lymphoma: Beyond the antitumour effect. Exp Hematol Oncol 2022;11(1):60. Abstract
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract